Genetic testing for prevention of severe drug‐induced skin rash
Información
- DOI:
- https://doi.org/10.1002/14651858.CD010891Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 19 diciembre 2013see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Piel
- Copyright:
-
- Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
AA was the contact person with the editorial base.
AA co‐ordinated the contributions from the co‐authors and wrote the final draft of the protocol.
AA, AJ, and MP worked on the methods sections.
AA, MP, and BM drafted the clinical sections of the background and responded to the clinical comments of the referees.
AJ responded to the methodology and statistics comments of the referees.
MP, AJ, BM, and LHS contributed to writing the protocol.
LHS was the consumer co‐author and checked the protocol for readability and clarity. She also ensured that the outcomes are relevant to consumers.
AA is the guarantor of the final review.
Disclaimer
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health, UK.
Sources of support
Internal sources
-
No financial support, Other.
External sources
-
The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group.
Declarations of interest
Ana Alfirevic: none declared.
Munir Pirmohamed: none declared.
Branka Marinovic: none declared.
Andrea L Jorgensen: none declared.
Linda Harcourt‐Smith: none declared.
Olivier Chosidow, clinical referee, works in a department that is a referral center for toxic and auto‐immune blistering diseases, and he has participated in the RegiSCAR (European Registry of Severe Cutaneous Adverse Reactions) group.
Acknowledgements
The Cochrane Skin Group editorial base wishes to thank Luigi Naldi who was the Cochrane Dermatology Editor for this protocol; Jo Leonardi‐Bee and Ching‐Chi Chi who were the Statistical and Methods Editors, respectively; the clinical referee, Olivier Chosidow; and the consumer referee, Jack Tweed.
Version history
| Published | Title | Stage | Authors | Version |
| 2019 Jul 17 | Genetic testing for prevention of severe drug‐induced skin rash | Review | Ana Alfirevic, Munir Pirmohamed, Branka Marinovic, Linda Harcourt‐Smith, Andrea L Jorgensen, Tess E Cooper | |
| 2013 Dec 19 | Genetic testing for prevention of severe drug‐induced skin rash | Protocol | Ana Alfirevic, Munir Pirmohamed, Branka Marinovic, Andrea L Jorgensen, Linda Harcourt‐Smith | |
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Humans;
PICO
Flowchart of interventions (genetic testing) and outcomes (skin rash) in a patient population prescribed drug X
| Term | Explanation |
| Allele | One of two or more alternative forms of a gene at corresponding sites (loci) on homologous chromosomes |
| Hardy‐Weinberg equilibrium | This states that allele and genotype frequencies in a population will remain constant from generation to generation in the absence of other evolutionary influences |
| HLA | Human leukocyte antigen: a group of protein molecules located on bone marrow and other cells that can provoke an immune response |
| Hypersensitivity | A state of altered reactivity in which the body reacts with an exaggerated immune response to a foreign substance, such as a drug |
| Polymorphic | A variation in the DNA that is too common to be due merely to new mutation. A polymorphism must have a frequency of at least 1% in a population |
| Maculopapular rash | A rash with both macules (flat and coloured like a freckle) and papules (a small raised spot) |
| Drugs associated with skin injury | Class of drug | HLA allele | Population | Reference |
| Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) | ||||
| Allopurinol | Antiuric acid | B*5801 | Han Chinese | |
| ‐ | ‐ | ‐ | Thai | |
| ‐ | ‐ | ‐ | Japanese | |
| ‐ | ‐ | ‐ | Malay | |
| Carbamazepine | Antiepileptic | B*1502 | Han Chinese | |
| ‐ | ‐ | ‐ | Thai | Kulkantrakorn 2012; Locharernkul 2008; Tassaneeyakul 2010; Tangamornsuksan 2013 |
| ‐ | ‐ | ‐ | Malay | |
| ‐ | ‐ | ‐ | Indian | |
| ‐ | ‐ | A*3101 | White | |
| ‐ | ‐ | A*3101 | Japanese | |
| Phenytoin | Antiepileptic | B*1502 | Han Chinese | |
| ‐ | ‐ | ‐ | Thai | |
| Oxicam | Non‐steroidal anti‐inflammatory drug (NSAID) | A2, B12 | White | |
| Sulphamethoxazole | Antibiotic | A29, B12, DR7 | White | |
| Hypersensitivity syndrome (DIHS or DRESS) | ||||
| Abacavir | Antiretroviral | B*5701 | White | Hetherington 2002; Hughes 2004; Mallal 2002; Mallal 2008; Martin 2004 |
| ‐ | ‐ | ‐ | African Americans | |
| Aminopenicillins | Antibiotic | A2, Drw52 | White | |
| Nevirapine | Antiretroviral | DRB1*01 | White ‐ Australian | |
| ‐ | ‐ | DRB1*01 | White ‐ French | |
| ‐ | ‐ | Cw8, B14 | White ‐ Italian | |
| ‐ | ‐ | Cw8 | Japanese | |
| ‐ | ‐ | B*3505 | Thai | |
| ‐ | ‐ | Cw4 | Thai | |
| ‐ | ‐ | C*0404 | Black African | |
| ‐ | ‐ | Cw*04 | Chinese | |
| Aspirin | NSAIDS | DRB1*1302, DQB1*0609 | ‐ | |
| ‐ | NSAIDS | DR11 | ‐ | |
| Iodine contrast media | ‐ | DR | White ‐ Spanish | |
| Paraphenylenediamine | Hair dye | DP | White ‐ German | |
| Gold sodium thiomalate | Treatment of rheumatoid arthritis | DR5 | White ‐ Spanish | |
| Lamotrigine | Antiepileptic | B*5801, A*6801 | White | |
| Trichloroethylene | Industrial solvent, dry cleaning | B*1301 | Japanese | |
| Fixed drug eruptions | ||||
| Co‐trimoxazole | Antibiotic | A30, B13, Cw6 | White ‐ Turkish | |
| Feprazone | Analgesic | B22 | ‐ |
